No Data
The Market Doesn't Like What It Sees From Shanghai Junshi Biosciences Co., Ltd.'s (HKG:1877) Revenues Yet
Hong Kong stocks fluctuated | Pharmaceutical stocks generally declined as the Trump administration launched an investigation into pharmaceuticals, but Institutions remain Bullish on the growth potential of Innovative Drugs.
Pharmaceutical stocks generally fell. As of the time of writing, ASCLETIS-B (01672) dropped 12.64%, trading at 5.46 Hong Kong dollars; ALPHAMAB-B (09966) fell 7.74%, trading at 6.44 Hong Kong dollars; HBM HOLDINGS-B (02142) decreased by 7.31%, trading at 7.1 Hong Kong dollars.
Hong Kong stock movement | JUNSHI BIO (01877) is currently up over 7%. The chairman plans to increase Shareholding by no less than 0.1 billion yuan in shares. The company will release its first-quarter results at the end of the month.
JUNSHI BIO (01877) is currently up over 7%, with a rise of 7.39% at the time of writing, trading at 15.12 Hong Kong dollars, with a transaction amount of 25.8589 million Hong Kong dollars.
Express News | Junshi Biosciences Says Chairman Plans to Boost Holdings in Co a/H-Shares Worth at Least 100 Mln Yuan
JUNSHI BIO (01877.HK) plans to hold a Board of Directors meeting on April 25 to approve the first-quarter performance.
Gelonghui reported on April 10 that JUNSHI BIO (01877.HK) announced that a Board of Directors meeting is scheduled for April 25, 2025 (Friday) to consider and approve the unaudited financial results of the group for the three months ended March 31, 2025.
JUNSHI BIO: DATE OF BOARD MEETING
Further Weakness as Shanghai Junshi Biosciences (HKG:1877) Drops 3.2% This Week, Taking Three-year Losses to 83%
